BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
See today's BioWorld
Home
» Japan's PMDA flags Kyowa Hakko Kirin's filgrastim, biosimilars with anaphylaxis risk
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Japan's PMDA flags Kyowa Hakko Kirin's filgrastim, biosimilars with anaphylaxis risk
Aug. 24, 2016
By
Richard Smart
No Comments
TOKYO – Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has issued a risk warning for filgrastim and a number of its biosimilars after reports that it can lead to anaphylaxis.
BioWorld